Recent research highlights the pivotal role of co-stimulatory molecules, including CD28 and CD137, in regulating T-cell metabolic pathways, offering promising targets for immunotherapy to boost T-cell anti-tumor activity. This evidence concerns the gene TNFRSF9 and neoplasm.